Acupuncture for Plantar Fasciosis in the Primary Care Setting
Plantar Fascitis
Bottom Line
View on ClinicalTrials.gov: NCT03246087 ↗Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Acupunture (Device); Standard of care (Other)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Mike O'Callaghan Military Hospital
- Primary completion
- Apr 2019
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY NPRS-11 |
3.8; 4.3; 3.7; 3.1; 3.7; 3.0 | — |
| SECONDARY FFI-R |
73; 70; 63; 61; 64; 60 | — |
Summary
Eligibility Criteria
THIS STUDY IS BEING CONDUCTED AT A MILITARY INSTALLATION. YOU MUST HAVE MILITARY INSURANCE IN ORDER TO PARTICIPATE IN THIS STUDY.
Inclusion Criteria
Male and female DoD beneficiaries, age 18 years or older, who have been diagnosed with plantar fasciitis/fasciosis OR Patients meeting criteria of pain in the bottom of the foot/heel with first steps in the morning & tender to palpation over the medial calcaneal tubercle (where the plantar fascia inserts). Those with acute and chronic diagnoses will be included.
Exclusion Criteria
- Pregnant
- Absence of leg
- Active cellulitis of lower extremity
- Prior surgery for plantar fasciitis
- Steroid injections in the last 12 weeks for plantar fasciitis; if received in last 12 weeks subjects will be offered to be involved in the study after they have completed a 12 week wash out period.
- Any regenerative therapy to include proliferation therapy or platelet rich plasma therapy in the last 12 weeks for plantar fasciitis; if received in last 12 weeks subject will be offered to be involved in the study after they have completed a 12 week wash out period.
- Botox injections for plantar fasciitis injections in the last 12 weeks for plantar fasciitis; if received in last 12 weeks subject will be offered to be involved in the study after they have completed a 12 week wash out period.
- Use of anticoagulants
- If they have every had any prior acupuncture for plantar fasciitis using the defined KB-2 points
Data sourced from ClinicalTrials.gov (NCT03246087). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.